
Atebimetinib shows promising 1-year survival rates in pancreatic cancer patients, potentially transforming treatment options with manageable safety profiles.

Atebimetinib shows promising 1-year survival rates in pancreatic cancer patients, potentially transforming treatment options with manageable safety profiles.

The FDA awarded fast track designation to a trispecific antibody targeting BCMA, GPRC5D, and CD3 in multiple myeloma.

Explore the evolving landscape of myelodysplastic syndromes management, highlighting personalized therapies and novel treatment strategies for better patient outcomes.

New trial results reveal zanidatamab significantly improves survival in HER2-positive advanced gastroesophageal adenocarcinoma, challenging existing treatment standards.

New findings reveal that tafasitamab significantly enhances progression-free survival in relapsed follicular lymphoma when combined with lenalidomide and rituximab.

The FDA gave clearance to the IND for a randomized trial of the DNA vaccine iSCIB1+ based on positive single-arm data in combination with dual checkpoint inhibitors.

Experts discuss second-line treatment strategies for clear cell renal cell carcinoma, focusing on efficacy, tolerability, and the role of tivozanib.

New research reveals comparable outcomes for STZ/5-FU and everolimus in treating advanced pancreatic neuroendocrine tumors, guiding personalized treatment strategies.

Higher doses of anti–T-lymphocyte globulin significantly reduce chronic graft-vs-host disease in matched sibling stem cell transplants, enhancing patient outcomes.

Deb Schrag, MD, emphasizes AI's role in enhancing cancer care, addressing early-onset cancers, and improving workforce well-being as she prepares for ASCO leadership.

Marginal zone lymphoma treatment evolves with promising CAR T-cell therapies, addressing unmet needs in aggressive cases and improving patient outcomes.

Discover the latest breakthroughs in oncology, including FDA approvals and promising trial results for advanced breast cancer and metastatic colorectal cancer.

During a live event, Andrew H. Lipsky, MD, and participants discuss emerging trial data and real-world applications of innovative CLL treatment combinations.

Researchers explore a promising nonchemotherapy treatment for low-grade serous ovarian cancer, combining ribociclib and letrozole to improve patient outcomes.

The ROSELLA trial reveals relacorilant plus nab-paclitaxel significantly improves survival in platinum-resistant ovarian cancer without increasing safety risks.

FDA approves Guardant360 CDx for identifying BRAF V600E-mutant colorectal cancer patients, enhancing precision therapy with encorafenib and cetuximab.

Cervical cancer treatment evolves with molecular screening and immunotherapies, emphasizing early detection as key to improving patient outcomes.

FDA designates OPN-2853 as an orphan drug for myelofibrosis, showing promising results in spleen size reduction and safety in clinical trials.

New cancer vaccine MVP-S shows promising results in recurrent ovarian cancer, enhancing immune response and improving treatment outcomes with pembrolizumab.

Combination therapies using PD-1/PD-L1 inhibitors enhance survival rates in relapsed/refractory acute lymphoblastic leukemia without added toxicity.

A groundbreaking study reveals that sacituzumab govitecan and pembrolizumab significantly enhance survival in patients with untreated metastatic triple-negative breast cancer.

A groundbreaking trial reveals the promising efficacy of fruquintinib and sintilimab for advanced endometrial cancer, offering new hope for patients.

The FDA released draft guidance on minimal residual disease and complete response as trial end points to accelerate multiple myeloma drug approvals.

A new study reveals that combining ianalumab with ibrutinib offers promising results for chronic lymphocytic leukemia, enabling some patients to stop therapy.

Nivolumab after CAR T-cell therapy failure produced responses in only a small percentage of patients with myeloma or non-Hodgkin lymphoma, although responses in myeloma appeared durable.

FDA fast-tracks BNT113, an mRNA immunotherapy, for treating HPV16+ head and neck cancer, enhancing immune responses alongside pembrolizumab.

The FDA designates soficabtagene geleucel as a breakthrough therapy, highlighting its potential in treating relapsed T cell leukemia and lymphoma.


In an interview with Targeted Oncology, George Mulligan, PhD, discussed the key takeaways from analysis of the Immune Atlas for multiple myeloma and what will come next now that this data set has been made available.

The FDA granted Orphan Drug Designation to LP-284, a small molecule targeting DNA damage repair mechanisms, for soft tissue sarcoma.